Autolus ups guidance after rapid commercial ramp

 

Autolus raises 2026 AUCATZYL revenue guidance to $140–$150M as Q2 sales and gross margin inflect sharply

• Autolus beat fiscal Q2 2026 estimates with non-GAAP EPS $-0.15.
• AUCATZYL Q2 revenue reached $45.7m, up from $20.9m last year and $26.2m Q1.
• 2026 AUCATZYL net product revenue guidance raised from $120–135m to $140–150m.
• Gross margin improved to 55% from 6% in Q1 and negative in 2025.
• Management targets 65–70% gross margin for adult ALL within 12–18 months.
• Over 80 U.S. centers now activated; aiming for 90+ U.S. and ~20 U.K. by year-end.
• Company remains loss-making, with Q2 net loss of $39.1m, though losses narrowed YoY.
• New Perceptive Advisors credit facility (up to $250m) extends cash runway into Q2 2028.
• Guidance embeds prudence and potential seasonality; implies flattish-to-slightly-below Q2 revenue run-rate.
• U.K. launch off to positive start but currently contributes substantially less than 10% of U.S. sales.
• Multiple 2027–2028 data catalysts in pediatric ALL, lupus nephritis, systemic lupus, and progressive MS.
• Main concern: achieving sustainable profitability while still dependent on a single commercial asset as pipeline matures.
• Strong quarter, driven by rapid AUCATZYL commercial ramp and substantial gross margin improvement.

https://finviz.com/stock?t=AUTL&p=d